Lab result explainedInflammationLast updated November 10, 2026

ANA test: what a positive ANA, titers like 1:80 and 1:160, and patterns mean

Antinuclear antibody test (ANA) · ANA screen with reflex to titer and pattern (often with ENA panel) · reported in Titer (1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560) with a pattern; solid-phase assays report an index or ratio (negative below 1.0 at most labs)

The antinuclear antibody (ANA) test looks for antibodies that react against the contents of your own cells' nuclei, and it is the standard screening test when a clinician suspects systemic lupus erythematosus or a related autoimmune connective tissue disease. Results are reported as a titer, which is the highest dilution of your serum at which the antibodies are still detectable (1:40, 1:80, 1:160, 1:320, 1:640, 1:1280 and so on), and a pattern, which describes how the antibodies stain the cell under the microscope (homogeneous, speckled, nucleolar, centromere and others).

A positive ANA is common and, on its own, does not mean you have an autoimmune disease. About 30 percent of healthy adults are positive at 1:40, about 13 percent at 1:80 and about 5 percent at 1:160, with higher rates in women and with age. Because lupus affects fewer than 1 in 1,000 people, most people with a low-positive ANA and no symptoms will never develop it. The test is valuable because it is so sensitive: more than 95 percent of people with lupus have a positive ANA, so a negative result makes lupus very unlikely.

What turns a positive ANA into a diagnosis is the combination of the titer, the pattern, your symptoms and the follow-on tests. A titer of 1:160 or higher with a homogeneous pattern and positive anti-double-stranded DNA antibodies in a woman with joint pain, a facial rash and mouth ulcers is lupus until proven otherwise; a 1:80 dense fine speckled pattern in someone who feels well is, in most cases, a finding to note and move on from.

ANA at a glance

What it is: a screening test for antibodies against your own cell nuclei, done by immunofluorescence on HEp-2 cells and reported as a titer and a pattern.
Negative: below 1:80 at most US labs (some still use 1:40). The 2019 EULAR/ACR lupus classification criteria require an ANA of at least 1:80.
Positive: 1:80 is low positive and found in about 13 percent of healthy people; 1:160 is moderately positive (about 5 percent of healthy people); 1:320 and higher is strongly positive and much more likely to reflect autoimmune disease.
Patterns: homogeneous suggests lupus or drug-induced lupus; speckled suggests lupus, Sjögren's, mixed connective tissue disease or scleroderma; centromere suggests limited scleroderma; nucleolar suggests systemic sclerosis; dense fine speckled (DFS70) is usually benign.
A positive ANA with no symptoms usually needs nothing more than a note in the record and a review if symptoms appear; the titer does not track disease activity.
Next step after a positive result: an ENA panel (anti-dsDNA, Sm, RNP, Ro/SSA, La/SSB, Scl-70, centromere, Jo-1), complement C3 and C4, CBC, urinalysis and creatinine, interpreted with your symptoms.

Have your whole report? Paste it into the free Lab Explainer

Every marker explained in plain language, in context with the others, with questions to bring to your appointment. No account needed.

What ANA measures

Antinuclear antibodies are autoantibodies, mostly IgG, directed at proteins and nucleic acids inside the nucleus: DNA, histones, the nucleosome, small nuclear ribonucleoproteins (Sm, RNP), Ro and La, topoisomerase I (Scl-70), centromere proteins and nucleolar components. In lupus and related diseases, dying cells are cleared poorly, nuclear material is exposed to the immune system, and tolerance to it breaks down. The antibodies are a marker of that process and, in the case of anti-dsDNA, also contribute to kidney damage by forming immune complexes.

The reference method, recommended by the American College of Rheumatology, is indirect immunofluorescence. Your serum is diluted in a series of steps (1:40, 1:80, 1:160 and so on), each dilution is layered over a slide of human HEp-2 cells, and a fluorescent anti-human antibody reveals where your antibodies have bound. The titer is the last dilution that still shows staining; the pattern is where the staining sits. Some laboratories screen instead with a solid-phase immunoassay (ELISA or multiplex bead assay) that reports a ratio or index rather than a titer; these are faster and more reproducible but miss some antibodies the cell-based test detects and detect some it does not, so results from the two methods are not interchangeable.

The International Consensus on ANA Patterns (ICAP) now standardises pattern names with AC codes: AC-1 homogeneous, AC-2 dense fine speckled, AC-3 centromere, AC-4 and AC-5 fine and coarse speckled, AC-8 to AC-10 nucleolar, and AC-15 to AC-23 for cytoplasmic patterns, which are not strictly nuclear but are reported because some (such as the cytoplasmic speckled pattern of anti-Jo-1 in myositis or the reticular pattern of anti-mitochondrial antibodies in primary biliary cholangitis) are diagnostically important. A positive ANA is a screening result; the specific antibodies are identified by the extractable nuclear antigen (ENA) panel and anti-dsDNA tests that follow.

Normal range for ANA

Reference ranges vary between labs and by age, sex and pregnancy. Use the range printed on your own report.

Group	Typical range (Titer (1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560) with a pattern; solid-phase assays report an index or ratio (negative below 1.0 at most labs))	Notes
Negative	Below 1:80 (some labs below 1:40)	Lupus is very unlikely with a negative immunofluorescence ANA; fewer than 2 to 5 percent of people with lupus are ANA-negative, usually those with isolated anti-Ro antibodies.
Borderline / low positive	1:40	Found in about 30 percent of healthy adults. Most labs no longer report 1:40 as positive.
Low positive	1:80	About 13 percent of healthy adults, more in women and after age 60. Entry criterion for the 2019 EULAR/ACR lupus classification criteria, but on its own the positive predictive value for lupus is low.
Moderate positive	1:160	About 5 percent of healthy adults. Warrants an ENA panel and anti-dsDNA if there are any symptoms.
High positive	1:320 to 1:640	About 3 percent of healthy adults at 1:320. Increasingly likely to reflect autoimmune disease, especially with a homogeneous, centromere or nucleolar pattern.
Very high positive	1:1280 and above	Strongly suggests an autoimmune connective tissue disease; healthy people rarely reach this level.
Solid-phase (ELISA / multiplex) screen	Index below 1.0 negative; 1.0–2.9 weak; 3.0–5.9 moderate; 6.0 or more strong (ranges vary by kit)	Not equivalent to a titer. A positive solid-phase screen is often reflexed to immunofluorescence for titer and pattern.
Pattern guide	Homogeneous (AC-1): lupus, drug-induced lupus, juvenile arthritis. Speckled (AC-4/5): lupus, Sjögren's, MCTD, scleroderma. Centromere (AC-3): limited scleroderma. Nucleolar (AC-8–10): systemic sclerosis. Dense fine speckled (AC-2): usually benign	Patterns suggest which specific antibodies to look for; they do not diagnose on their own.

Positive ANA

A positive ANA means antibodies against nuclear components were detected at the dilution reported. How much it matters depends on three things: the titer, the pattern and, above all, whether you have features of an autoimmune disease. A 1:80 result in someone with no symptoms is, statistically, far more likely to be one of the 13 percent of healthy positives than early lupus, and the usual advice is to record it and review if symptoms such as joint pain and swelling, a photosensitive rash, mouth ulcers, Raynaud's, dry eyes and mouth, pleuritic chest pain, unexplained fevers or hair loss appear. A titer of 1:320 or higher, or any positive ANA with those symptoms, needs the specific antibody tests and a rheumatology assessment.

The pattern narrows the search. A homogeneous pattern points toward antibodies to dsDNA, histones or nucleosomes and is the classic lupus pattern, though it is also the pattern of drug-induced lupus from hydralazine, procainamide, minocycline, isoniazid and TNF-inhibitor biologics. A speckled pattern is the most common positive pattern and is associated with anti-Ro/SSA and anti-La/SSB (Sjögren's syndrome, subacute cutaneous lupus, neonatal lupus risk in pregnancy), anti-Sm (highly specific for lupus), anti-RNP (mixed connective tissue disease) and, at low titer, many healthy people. A centromere pattern is strongly linked to limited cutaneous systemic sclerosis (CREST), and a nucleolar pattern to diffuse systemic sclerosis. The dense fine speckled pattern, caused by anti-DFS70 antibodies, is found in up to a third of ANA-positive healthy people and, when it is the only antibody present, argues against a systemic autoimmune rheumatic disease.

A positive ANA also occurs in conditions outside rheumatology: autoimmune thyroid disease (Hashimoto's and Graves'), autoimmune hepatitis and primary biliary cholangitis, infections such as hepatitis C, EBV, HIV, tuberculosis and endocarditis (often transient), some cancers and lymphomas, and simply older age. Once positive, the ANA titer tends to stay roughly where it is and does not rise and fall with disease activity, so repeating it to monitor lupus is not useful; anti-dsDNA and complement levels do that job.

Common causes

Systemic lupus erythematosus (SLE)
ANA positive in 95 to 98 percent, typically 1:160 or higher with a homogeneous or speckled pattern. Confirmed by anti-dsDNA (about 70 percent of patients, highly specific) and anti-Sm (about 25 percent, very specific), with low complement C3 and C4 in active disease.
Healthy people, particularly women and older adults
The most common reason for a low-positive ANA. About 13 percent of the US population is positive at 1:80 and 5 percent at 1:160; prevalence rises with age and is roughly twice as high in women. Many of these people carry anti-DFS70 antibodies, which are not linked to disease.
Sjögren's syndrome
ANA positive in 70 to 90 percent, usually a fine speckled pattern with anti-Ro/SSA and often anti-La/SSB antibodies. Dry eyes, dry mouth, parotid swelling and fatigue are the main features.
Systemic sclerosis (scleroderma)
ANA positive in about 95 percent. A centromere pattern indicates limited disease (Raynaud's, calcinosis, telangiectasia, pulmonary hypertension risk); a nucleolar pattern or anti-Scl-70 (topoisomerase I) indicates diffuse disease with lung fibrosis risk.
Mixed connective tissue disease and overlap syndromes
High-titer speckled ANA (often 1:1280 or above) with anti-U1-RNP antibodies; features of lupus, scleroderma and myositis together with puffy hands and Raynaud's.
Drug-induced lupus
Hydralazine, procainamide, minocycline, isoniazid, methyldopa, quinidine, chlorpromazine, some anticonvulsants and TNF inhibitors (infliximab, adalimumab, etanercept, in which ANA conversion occurs in up to half of patients though lupus is uncommon). Homogeneous pattern with anti-histone antibodies; usually resolves after the drug is stopped.
Autoimmune liver disease
Type 1 autoimmune hepatitis (ANA and smooth muscle antibodies) and primary biliary cholangitis (anti-mitochondrial antibodies with nuclear rim or multiple nuclear dot ANA patterns).
Autoimmune thyroid disease
Low-titer ANA is found in 10 to 45 percent of people with Hashimoto's thyroiditis or Graves' disease, without implying a second autoimmune disease.
Infections
Hepatitis C, hepatitis B, EBV, parvovirus B19, HIV, tuberculosis, syphilis, malaria and bacterial endocarditis can produce a transient low-titer ANA that disappears over months.
Cancer and other conditions
Lymphoma, some solid tumors, idiopathic pulmonary fibrosis, inflammatory myositis (dermatomyositis and polymyositis, often with cytoplasmic patterns), juvenile idiopathic arthritis (where ANA positivity flags uveitis risk) and a first-degree relative with lupus (about 20 to 30 percent of unaffected relatives are ANA-positive).

Symptoms that can go with it

Often none; a low-positive ANA in a person who feels well is usually not a sign of illness
Joint pain, stiffness and swelling, typically in the hands, wrists and knees, worse in the morning
A rash across the cheeks and nose or elsewhere that flares after sun exposure, and mouth or nose ulcers
Unusual tiredness, low-grade fevers and unintended weight loss
Fingers turning white then blue in the cold (Raynaud's), puffy or tight skin on the fingers
Dry, gritty eyes and a dry mouth with difficulty swallowing dry food
Chest pain on breathing in (pleurisy or pericarditis), breathlessness
Hair thinning, foamy urine or ankle swelling (possible kidney involvement), new numbness or weakness

Read it alongside

ENA panel (anti-Sm, RNP, Ro/SSA, La/SSB, Scl-70, centromere, Jo-1) — identifies the specific antibody behind a positive ANA and points to the disease.
Anti-double-stranded DNA — specific for lupus and tracks disease activity, especially kidney involvement; the titer of the ANA itself does not.
Complement C3 and C4 — low levels in active lupus as immune complexes consume complement.
Complete blood count — anemia, low white cells and low platelets are lupus classification criteria and common in Sjögren's.
Urinalysis and creatinine — protein or blood in the urine with a positive ANA raises the possibility of lupus nephritis and needs prompt attention.
ESR and CRP — ESR is often high in active lupus while CRP stays low unless there is infection or serositis; a high CRP with lupus should prompt a search for infection.
Rheumatoid factor and anti-CCP — ordered when joint symptoms are prominent, to separate rheumatoid arthritis from lupus and to detect Sjögren's (RF is positive in most).
Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein) — checked in lupus and in anyone with a positive ANA and clots or pregnancy losses.

What usually happens next

If your ANA is positive, the result should be read alongside a symptom review and examination; without any features of autoimmune disease, a 1:80 or 1:160 result usually leads to watchful review rather than more tests.
If you have symptoms, or the titer is 1:320 or higher, expect an ENA panel, anti-dsDNA, complement C3 and C4, a CBC, urinalysis and creatinine, and often a referral to a rheumatologist.
Ask which method your lab used (immunofluorescence versus solid-phase); a positive solid-phase screen is often confirmed with an immunofluorescence titer and pattern before anything is concluded.
Review your medications: hydralazine, minocycline, isoniazid, procainamide and TNF inhibitors can all produce a positive ANA, and a recent viral illness can cause a transient one.
Repeating the ANA to monitor disease is not useful; if you have lupus, anti-dsDNA, complement and urine tests are what get tracked. A negative ANA does not need repeating unless new symptoms appear.
If you are pregnant or planning pregnancy with a positive anti-Ro/SSA, let your obstetrician know; it carries a small risk (about 2 percent) of congenital heart block that is monitored with fetal echocardiography.

Diet, lifestyle and natural levers with evidence

What can move ANA once the cause is known. Nothing here replaces finding the cause.

Nothing natural changes the ANA result itself

Strong evidence

Once antinuclear antibodies are present they tend to persist at a similar titer for years regardless of diet, supplements or lifestyle, and no food, herb or supplement has been shown in human trials to turn a positive ANA negative. The levers below affect what the test means or the course of the disease behind it, not the number.

Medications and infections that produce a positive ANA

Strong evidence

Drug-induced ANA from hydralazine, procainamide, minocycline, isoniazid, methyldopa and TNF-inhibitor biologics usually fades over months once the drug is stopped, and the transient ANA of hepatitis C, EBV, parvovirus and endocarditis clears as the infection resolves. If your positive ANA appeared after starting one of these drugs or during an illness, retesting 3 to 6 months later is more informative than any supplement.

Sun protection and smoking cessation if you have lupus

Moderate evidence

Ultraviolet light triggers skin and systemic lupus flares; daily broad-spectrum SPF 50 sunscreen reduced skin lesions in controlled studies and is a standard recommendation in EULAR lupus guidance. Smoking is associated with higher lupus disease activity, more skin disease and a poorer response to hydroxychloroquine, and in cohort studies ex-smokers have activity scores closer to never-smokers.

Vitamin D repletion in people with lupus who are deficient

Moderate evidence

Low 25-hydroxyvitamin D is common in lupus (sun avoidance and steroids), and in a 12-month randomised trial of 267 patients, 2,000 IU a day lowered disease activity scores and anti-dsDNA levels modestly compared with placebo. It did not change the ANA titer, and trials in ANA-positive people without lupus have not shown that it prevents progression to disease.

Check a 25-hydroxyvitamin D level and avoid high doses if you have kidney stones, high calcium or sarcoidosis.

When to see a clinician promptly

A positive ANA with foamy urine, blood in the urine, swollen ankles or rising blood pressure: possible lupus nephritis, which needs prompt assessment and a urine protein test within days, not weeks.
Chest pain that is worse on breathing in or lying flat, breathlessness, or a fast heartbeat with a positive ANA (pericarditis, pleurisy or a clot).
New severe headache, seizure, confusion, stroke-like weakness or visual loss in someone with lupus or a strongly positive ANA.
Fever with a positive ANA while taking immunosuppressants or steroids, since infection and flare can look alike and infection is the more dangerous.
Any positive ANA accompanied by joint swelling, a photosensitive rash, mouth ulcers, Raynaud's, dry eyes and mouth or unexplained fatigue and weight loss, to arrange specific antibody testing and a rheumatology opinion.
A positive ANA in pregnancy, particularly with anti-Ro/SSA antibodies, so that fetal heart monitoring can be arranged between 16 and 26 weeks.

Frequently asked questions

What does a positive ANA mean?

It means antibodies against components of your own cell nuclei were detected at the dilution reported. It is a screening result, not a diagnosis. Around 13 percent of healthy people are positive at 1:80 and 5 percent at 1:160, so a low-positive ANA without symptoms is usually not significant. A positive ANA with symptoms such as joint swelling, a sun-sensitive rash, mouth ulcers or dry eyes, or a titer of 1:320 or higher, needs further antibody tests and a specialist assessment.

Is an ANA titer of 1:80 bad?

Usually not. A titer of 1:80 is the lowest level most labs call positive and is found in about one in eight healthy adults, more often in women and after 60. It is the entry threshold for the lupus classification criteria only because the criteria are designed to miss no one; on its own, its positive predictive value for lupus in the general population is only a few percent. If you feel well, the usual plan is to note it and review if symptoms develop.

What does an ANA titer of 1:160 with a speckled pattern mean?

A 1:160 speckled ANA is moderately positive and is the most common significant result. Speckled staining comes from antibodies to Ro/SSA, La/SSB, Sm or RNP, so the next step is an ENA panel to see which, if any, is present: anti-Ro and anti-La suggest Sjögren's syndrome or subacute cutaneous lupus, anti-Sm is specific for lupus, and anti-RNP suggests mixed connective tissue disease. If the ENA panel is negative and you have no symptoms, 1:160 speckled is found in about 5 percent of healthy people and is often a benign dense fine speckled (DFS70) antibody.

What does a homogeneous ANA pattern mean?

A homogeneous pattern means the whole nucleus stains evenly, and it is produced by antibodies to double-stranded DNA, histones or nucleosomes. It is the classic pattern of systemic lupus and of drug-induced lupus (hydralazine, procainamide, minocycline, isoniazid, TNF inhibitors). The follow-up is an anti-dsDNA test and, if you take one of those drugs, anti-histone antibodies. At low titer a homogeneous pattern is also seen in healthy people and in autoimmune thyroid and liver disease.

Can you have a positive ANA and not have lupus?

Yes, and most people with a positive ANA do not. Lupus affects roughly 1 in 1,000 to 1 in 2,000 people, while 5 to 13 percent of the population has a positive ANA. Other explanations include Sjögren's syndrome, scleroderma, autoimmune thyroid or liver disease, medications, recent infections, older age and simply being one of the many healthy people who carry these antibodies. Among people referred to a rheumatologist because of a positive ANA, only a minority turn out to have an autoimmune rheumatic disease.

I have a positive ANA but no symptoms. Will I get lupus?

Probably not. Long-term studies of ANA-positive people without symptoms find that only a small minority develop a connective tissue disease over 5 to 10 years, and those who do usually have higher titers (1:320 or above), a specific antibody on the ENA panel such as anti-dsDNA, anti-Sm or anti-Ro, or a family history. A low-titer ANA with a negative ENA panel and a dense fine speckled pattern carries a particularly low risk. There is no treatment to prevent progression, so the sensible approach is to know the warning symptoms and be re-assessed if they appear.

Can an ANA be a false positive?

In the sense of being positive without disease, yes, frequently; that is the price of a test designed to miss almost no cases of lupus. Technically false positives also occur: solid-phase screening assays and immunofluorescence can disagree, and some labs' 1:40 cut-off labels nearly a third of healthy people positive. Infections, medications and age-related autoantibodies add to the count. The fix is not to repeat the ANA but to run the specific antibody tests and interpret everything alongside your symptoms.

Does a negative ANA rule out autoimmune disease?

It makes lupus very unlikely: fewer than 5 percent of people with lupus are ANA-negative by immunofluorescence, and most of those have anti-Ro antibodies that are detected on the ENA panel. It does not rule out rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, vasculitis, inflammatory bowel disease or many other autoimmune conditions, which do not produce antinuclear antibodies. If your symptoms persist, the work-up moves on to tests specific for those conditions.

References

ANA (antinuclear antibody) test. MedlinePlus, US National Library of Medicine (2023)View source
ANA test. Mayo Clinic (2024)View source
Tan EM, Feltkamp TE, Smolen JS, et al.. Range of antinuclear antibodies in 'healthy' individuals. Arthritis and Rheumatism (1997)
Satoh M, Chan EK, Ho LA, et al.. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis and Rheumatism (2012)
Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis and Rheumatology (2019)
Damoiseaux J, Andrade LEC, Carballo OG, et al.. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Annals of the Rheumatic Diseases (2019)
Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis and Rheumatism (Arthritis Care and Research) (2002)
Lane SK, Gravel JW. Clinical utility of common serum rheumatologic tests. American Family Physician (2002)
Systemic lupus erythematosus (SLE). Merck Manual Professional Version (2024)
Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Journal of Immunology Research (2014)
Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. Journal of Rheumatology (2013)
Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases (2019)

Worried about your number?

Ask AskMN what your ANA result could mean in the context of your other results, symptoms and medications. Free, unlimited, no account needed.

Ask about my ANA

This page is educational and is not medical advice or a diagnosis. Lab results have to be interpreted together with your history, symptoms and other results by a clinician who knows you. Do not start or stop a supplement to change a lab value before the cause is known.